Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Longboard Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 • Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA, Calif., August 3, 2023 – Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023. “We have made great progress in the first half of 2023 and look forward to completing enrollment for ..."
05/09/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 • LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track for second quarter 2023, with Phase 1 topline single-ascending dose data expected in fourth quarter 2023 • Ended first quarter 2023 with $76.1 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA, Calif., May 9, 2023 – Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a..."
03/02/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives • LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 • LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose data expected in the second half of 2023 • Ended 2022 with $67.6 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 • Further strengthened institutional shareholder base by completing a follow-on public offering of common stock in February 2023 with gross proceeds of $23.0 million • Longboard to host conference call..."
08/04/2022 8-K Quarterly results
Docs: "### Financial Tables Follow LONGBOARD PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 27,716 $ 66,346 Short-term investments 59,702 40,379 Prepaid expenses and other current assets 2,728 1,659 Total current assets 90,146 108,384 Right-of-use assets 355 521 Property and equipment 12 14 Other long-term assets — 33 Total assets $ 90,513 $ 108,952 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 602 $ 1,028 Accrued research and development expenses 4,215 2,245 Accrued compensation and related expenses 1,019 1,480 Accrued other expenses 1,345 352 Right-of-use liabilities, current portion 363 339 Total current liabilities 7,544 5,444 Right-of-use liabilities, net of current portion — 185 Commitments a..."
05/05/2022 8-K Quarterly results
Docs: "### Financial Tables Follow LONGBOARD PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 35,037 $ 66,346 Short-term investments 61,087 40,379 Prepaid expenses and other current assets 4,035 1,659 Total current assets 100,159 108,384 Right-of-use assets 438 521 Property and equipment 13 14 Other long-term assets 33 33 Total assets $ 100,643 $ 108,952 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,357 $ 1,028 Accrued research and development expenses 2,998 2,245 Accrued compensation and related expenses 443 1,480 Accrued other expenses 1,536 352 Right-of-use liabilities, current portion 350 339 Total current liabilities 6,684 5,444 Right-of-use liabilities, net of current portion 94 185 Commitme..."
03/03/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results  Successfully completed multiple ascending dose portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies  Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with developmental and epileptic encephalopathies in Q1 2022  IND-enabling preclinical studies for LP143 and LP659 ongoing  Continuing to strengthen key expertise and leadership"
08/09/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy